KalVista terminates $100M ATM sales agreement with Cantor Fitzgerald; no shares sold

KalVista Pharmaceuticals, Inc.

Terminated Controlled Equity Offering Sales Agreement with Cantor, effective Feb 14, 2024.
Agreement allowed up to $100M in common stock sales; company sold zero shares under it.
Cantor waived notice period, making termination immediate upon close of business Feb 14.
Termination has no effect on operations or capital; company retains other financing avenues.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

KalVista Pharmaceuticals, Inc. terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. valued at no shares sold under the agreement; aggregate offering price up to $100.0 million (effective 2024-02-14).

Action: termination
Agreement: atm program
Counterparty: Cantor Fitzgerald & Co.
Value: no shares sold under the agreement; aggregate offering price up to $100.0 million
Effective: 2024-02-14

Exact text from the filing

On February 14, 2024, KalVista Pharmaceuticals, Inc. (the “Company”) delivered a written notice of termination (the “Termination Notice”) of that certain Controlled Equity Offering Sales Agreement (the “Sales Agreement”), dated May 21, 2021, by and between the Company and Cantor Fitzgerald & Co., as sales agent (“Cantor”).

View on SEC.gov

Browse all material agreements →

KalVista Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-036224

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.